Bicycle therapeutics announces updated topline zelenectide pevedotin data and highlights 2025 strategic priorities and milestones

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced updated topline phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (muc). the company also announced recent accomplishments and.
BCYC Ratings Summary
BCYC Quant Ranking